205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
17.79%
Revenue growth at 50-75% of NXPI's 28.63%. Martin Whitman would worry about competitiveness or product relevance.
39.45%
Gross profit growth under 50% of NXPI's 173.53%. Michael Burry would be concerned about a severe competitive disadvantage.
272.17%
EBIT growth above 1.5x NXPI's 37.46%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
3330.00%
Operating income growth above 1.5x NXPI's 37.46%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
1429.41%
Net income growth above 1.5x NXPI's 161.83%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
2000.00%
EPS growth above 1.5x NXPI's 161.71%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
1900.00%
Diluted EPS growth above 1.5x NXPI's 161.71%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.63%
Share reduction while NXPI is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.39%
Reduced diluted shares while NXPI is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.80%
Dividend reduction while NXPI stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
121.91%
OCF growth above 1.5x NXPI's 5.16%. David Dodd would confirm a clear edge in underlying cash generation.
144.71%
Positive FCF growth while NXPI is negative. John Neff would see a strong competitive edge in net cash generation.
29.78%
10Y CAGR of 29.78% while NXPI is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
5.55%
5Y CAGR of 5.55% while NXPI is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
-18.54%
Negative 3Y CAGR while NXPI stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
128.04%
OCF/share CAGR of 128.04% while NXPI is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
53.26%
OCF/share CAGR of 53.26% while NXPI is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
6.84%
3Y OCF/share CAGR of 6.84% while NXPI is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-0.33%
Negative 10Y net income/share CAGR while NXPI is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-17.92%
Negative 5Y net income/share CAGR while NXPI is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-86.65%
Negative 3Y CAGR while NXPI is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
73.41%
Equity/share CAGR of 73.41% while NXPI is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
3.13%
Equity/share CAGR of 3.13% while NXPI is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-11.69%
Negative 3Y equity/share growth while NXPI is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
417.19%
Dividend/share CAGR of 417.19% while NXPI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
423.04%
Dividend/share CAGR of 423.04% while NXPI is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
262.50%
3Y dividend/share CAGR of 262.50% while NXPI is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
10.58%
AR growth of 10.58% while NXPI is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
-3.19%
Inventory is declining while NXPI stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-0.09%
Negative asset growth while NXPI invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
0.66%
BV/share growth of 0.66% while NXPI is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
No Data
No Data available this quarter, please select a different quarter.
-4.40%
Our R&D shrinks while NXPI invests at 0.53%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
7.21%
We expand SG&A while NXPI cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.